Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097150 | 0.95 | DHODH (0.41) | DHODHMAOBPDK1PDK2PDK3 | |
| SCHEMBL13106282 | 0.90 | CYSLTR2 (0.39) | DHODHMAOBPPARGCYP2D6 | |
| SCHEMBL13097158 | 0.90 | DHODH (0.42) | DHODHMAOBPDK1PDK2PDK3 | |
| SCHEMBL13097181 | 0.90 | MAOB (0.40) | MAOBCYP2D6 | |
| SCHEMBL13107297 | 0.86 | CYSLTR2 (0.39) | DHODHMAOBPPARGCYP2D6 | |
| SCHEMBL13097106 | 0.85 | MAOB (0.41) | MAOBPDK1PDK2PDK3PDK4 | |
| SCHEMBL13097444 | 0.82 | MAOB (0.53) | DHODHMAOBPPARG | |
| SCHEMBL13106532 | 0.82 | CYSLTR2 (0.38) | DHODHMAOBPPARGCYP2D6 | |
| SCHEMBL13096824 | 0.81 | CYP2D6 (0.49) | MAOBKMT2ACYP2D6 | |
| SCHEMBL13106279 | 0.81 | CYSLTR1 (0.47) | DHODHKMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | DHODH 294/4885MAOB 200/4885PDK1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.